OL Cariprazine 3070-301-001
Protocol: STUDY00004941
Full Title
A 26-week, Multicenter, Open-label, Fleible-dose Study to Evaluate the Long-term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants with Schizophrenia or ipolar I Disorder
Description
This is a 26-week open-label study to evaluate the safety and effectiveness of the study drug in the treatment of pediatric participants with schizophrenia or bipolar I disorder.

Technical Description

(CSR 200939856165) The purpose of this study is to evaluate the long-term safety and tolerability of cariprazine in the treatment of pediatric participants with schizophrenia or bipolar I disorder.
Compensation: No
Eligibility
Males and females ages 13 to 18 with schizophrenia or 10 to 18 years of age with bipolar I disorder may be eligible for the study.
Age Group: Adults
Principal Investigator: STEVEN DUBOVSKY
Contact(s)
SEVIE KANDEFER
sk293@buffalo.edu
+1 716-898-4038
Want to Learn More?
Let us know how the study team can reach you. If you do not hear back within 2 business days, reach out to the study team directly at the contact information above or email ctsiresearch@buffalo.edu and someone will assist you.